Overview

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

Status:
RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Genmab